Healthcare provider profile · identity verified

Leah Anderson

Nurse Practitioner · ROCK HILL, SC · NPI 1356715668

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	199	42
Furosemide	Furosemide	184	34
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	146	26
Lorazepam	Lorazepam	128	37
Sertraline Hcl	Sertraline Hcl	125	16
Tramadol Hcl	Tramadol Hcl	111	26
Mirtazapine	Mirtazapine	110	26
Trazodone Hcl	Trazodone Hcl	104	24
Eliquis	Apixaban	103	suppressed
Gabapentin	Gabapentin	103	20
Losartan Potassium	Losartan Potassium	90	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	74	43
Metoprolol Succinate	Metoprolol Succinate	70	12
Potassium Chloride	Potassium Chloride	70	12
Duloxetine Hcl	Duloxetine Hcl	65	suppressed
Atorvastatin Calcium	Atorvastatin Calcium	63	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	61	15
Quetiapine Fumarate	Quetiapine Fumarate	59	suppressed
Metformin Hcl	Metformin Hcl	58	12
Sodium Chloride	0.9 % Sodium Chloride	58	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	57	12
Hydroxyzine Hcl	Hydroxyzine Hcl	52	19
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	52	26
Permethrin	Permethrin	52	20
Jardiance	Empagliflozin	51	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	50	suppressed
Allopurinol	Allopurinol	48	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	47	suppressed
Lacosamide	Lacosamide	46	suppressed
Amlodipine Besylate	Amlodipine Besylate	45	suppressed
Januvia	Sitagliptin Phosphate	40	suppressed
Ondansetron Hcl	Ondansetron Hcl	38	12
Hydrochlorothiazide	Hydrochlorothiazide	36	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	35	suppressed
Oxycontin	Oxycodone Hcl	35	suppressed
Carvedilol	Carvedilol	34	suppressed
Hydralazine Hcl	Hydralazine Hcl	33	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	31	21
Farxiga	Dapagliflozin Propanediol	31	suppressed
Ondansetron Odt	Ondansetron	31	15
Ibuprofen	Ibuprofen	30	suppressed
Lactulose	Lactulose	30	suppressed
Divalproex Sodium	Divalproex Sodium	28	suppressed
Novolog Flexpen	Insulin Aspart	28	suppressed
Omeprazole	Omeprazole	28	suppressed
Oxycodone Hcl	Oxycodone Hcl	28	11
Divalproex Sodium Er	Divalproex Sodium	26	suppressed
Aripiprazole	Aripiprazole	25	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	suppressed
Levofloxacin	Levofloxacin	21	17
Nystatin	Nystatin	21	14
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	18
Clonazepam	Clonazepam	20	suppressed
Latanoprost	Latanoprost	19	suppressed
Olanzapine	Olanzapine	19	suppressed
Alprazolam	Alprazolam	18	suppressed
Fluconazole	Fluconazole	18	17
Acetylcysteine	Acetylcysteine	17	suppressed
Humalog Kwikpen U-100	Insulin Lispro	17	suppressed
Morphine Sulfate	Morphine Sulfate	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Budesonide	Budesonide	16	suppressed
Lamotrigine	Lamotrigine	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Prednisone	Prednisone	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Moxifloxacin	Moxifloxacin Hcl	15	14
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Torsemide	Torsemide	15	suppressed
Clonidine	Clonidine	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	11
Levetiracetam	Levetiracetam	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Vascepa	Icosapent Ethyl	13	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Acarbose	Acarbose	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error